(0.06%) 5 472.82 points
(0.09%) 39 145 points
(0.37%) 17 783 points
(0.05%) $80.87
(-3.66%) $2.66
(-0.78%) $2 312.60
(0.21%) $28.93
(3.64%) $1 022.30
(0.28%) $0.936
(0.69%) $10.68
(0.45%) $0.792
(-0.28%) $87.25
Live Chart Being Loaded With Signals
Valneva SE, a specialty vaccine company, focuses on the development and commercialization of prophylactic vaccines for infectious diseases with unmet needs...
Stats | |
---|---|
今日成交量 | 5 752 |
平均成交量 | 10 903 |
市值 | 507.91M |
EPS | $0.420 ( Q1 | 2024-03-31 ) |
下一个收益日期 | ( $-0.390 ) 2024-09-19 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E |
-17.80 (Sector) 42.63 (Industry) 24.32 |
ATR14 | $0.111 (1.52%) |
Valneva SE 财务报表
Annual | 2023 |
营收: | $153.71M |
毛利润: | $48.54M (31.58 %) |
EPS: | $-0.730 |
FY | 2023 |
营收: | $153.71M |
毛利润: | $48.54M (31.58 %) |
EPS: | $-0.730 |
FY | 2022 |
营收: | $361.30M |
毛利润: | $36.86M (10.20 %) |
EPS: | $-1.240 |
FY | 2021 |
营收: | $348.09M |
毛利润: | $160.17M (46.01 %) |
EPS: | $-0.700 |
Financial Reports:
No articles found.
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Valneva SE
Valneva SE, a specialty vaccine company, focuses on the development and commercialization of prophylactic vaccines for infectious diseases with unmet needs. Its commercial vaccines for travelers include IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing Enterotoxigenic Escherichia coli bacterium; and VLA2001, a vaccine candidate against SARS-CoV-2. The company also develops VLA15, a vaccine candidate that has completed Phase II clinical trial against Borrelia; and VLA1553, a vaccine candidate, which is in Phase III clinical trial against the chikungunya virus. It sells its products in the United States, Canada, Germany, Austria, Nordics, the United Kingdom, other European countries, and internationally. Valneva SE has collaborations with Pfizer, Inc. to co-develop and commercialize its Lyme disease vaccine; and Instituto Butantan for the development, manufacturing, and marketing of single-shot chikungunya vaccine. The company was founded in 1998 and is headquartered in Saint-Herblain, France.
关于 实时信号
此页面上呈现的实时信号有助于确定何时购买或出售NA. 信号具有高达1分钟的延迟;与所有市场信号一样,存在误差或错误的可能性。
实时交易信号不是绝对的,getagraph.com 对基于这些信号采取的任何行动概不负责,如《使用条款》中所述。这些信号是基于广泛的技术分析指标。